Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P08887: Variant p.Ile279Asn

Interleukin-6 receptor subunit alpha
Gene: IL6R
Feedback?
Variant information Variant position: help 279 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance
Residue change: help From Isoleucine (I) to Asparagine (N) at position 279 (I279N, p.Ile279Asn). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from medium size and hydrophobic (I) to medium size and polar (N) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -3 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page
Variant description: help In HIES5; decreased STAT1 and STAT3 phosphorylation. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 279 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 468 The length of the canonical sequence.
Location on the sequence: help AERSKTFTTWMVKDLQHHCV I HDAWSGLRHVVQLRAQEEFG The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences. 
Human                         AERSKTFTTWMVKDLQHHCVIHDAWSGLRHVVQLRAQEEFG

Mouse                         PVWSKEFTVLLLPVAQYQCVIHDALRGVKHVVQVRGKEELD

Rat                           PVWSKXFTVWPLQVAQHQCVIHDALRGVKHVVQVRGKEEFD

Pig                           AERSKTFTTWMVKELQHHCIIHDAWSGMRHVVQLRAQEEFG
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 20 – 468 Interleukin-6 receptor subunit alpha
Chain 20 – 355 Soluble interleukin-6 receptor subunit alpha
Topological domain 20 – 365 Extracellular
Domain 218 – 316 Fibronectin type-III 2
Mutagenesis 277 – 277 C -> D. 30% increase of ligand-binding and 100% increase in IL6 signaling.
Mutagenesis 278 – 278 V -> N. 50% Decrease of ligand-binding and 50% increase in IL6 signaling.
Mutagenesis 279 – 279 I -> D. Complete loss of ligand-binding.
Mutagenesis 280 – 280 H -> I. No change of ligand-binding and no IL6 signaling.
Mutagenesis 281 – 281 D -> G. 70% decrease of ligand-binding and no IL6 signaling.
Mutagenesis 285 – 285 G -> D. 80% decrease of ligand-binding and no IL6 signaling.
Mutagenesis 291 – 291 Q -> K. Complete loss of ligand-binding.
Mutagenesis 293 – 293 R -> G. Complete loss of ligand-binding.
Beta strand 275 – 281



Literature citations
Loss of the interleukin-6 receptor causes immunodeficiency, atopy, and abnormal inflammatory responses.
Spencer S.; Koestel Bal S.; Egner W.; Lango Allen H.; Raza S.I.; Ma C.A.; Guerel M.; Zhang Y.; Sun G.; Sabroe R.A.; Greene D.; Rae W.; Shahin T.; Kania K.; Ardy R.C.; Thian M.; Staples E.; Pecchia-Bekkum A.; Worrall W.P.M.; Stephens J.; Brown M.; Tuna S.; York M.; Shackley F.; Kerrin D.; Sargur R.; Condliffe A.; Tipu H.N.; Kuehn H.S.; Rosenzweig S.D.; Turro E.; Tavare S.; Thrasher A.J.; Jodrell D.I.; Smith K.G.C.; Boztug K.; Milner J.D.; Thaventhiran J.E.D.;
J. Exp. Med. 216:1986-1998(2019)
Cited for: INVOLVEMENT IN HIES5; VARIANTS HIES5 ASN-279 AND PRO-280; CHARACTERIZATION OF VARIANTS HIES5 ASN-279 AND PRO-280; FUNCTION;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.